On June 9, 2022, the U.S. Food and Drug Administration (FDA) approved the FoundationOne®CDx as a companion diagnostic for two entrectinib indications:
Both indications are for patients who may be appropriate for treatment with entrectinib.
For more information, read Foundation Medicine's announcement and Roche's announcement.
Posted 6/9/2022
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
